To assess the effect of neurobehavioral dysfunction on amyotrophic lateral sclerosis (ALS) survival and on the use of life-prolonging therapies in a population-based setting.
METHODS The Piemonte and Valle d'Aosta Register for ALS (PARALS) is a prospective epidemiologic register established in 1995 collecting all ALS incident cases in 2 Italian regions (population: 4,332,842). Methods and epidemiologic data have been reported in detail elsewhere. 7 ALS diagnosis was based on the El Escorial diagnostic criteria (EEC) and the EEC revised criteria. 8, 9 All the 132 patients with ALS diagnosed in the Province of Torino (population, 2,236,941) between January 1, 2007, and June 30, 2008, identified through the PARALS, were invited to participate in this longitudinal study. Of these, 128 agreed, 2 refused, and 2 had no caregivers available for completing the questionnaire. Only subjects with definite, probable, and probable laboratory-supported ALS according to EEC were eligible. The interview was performed within 4 months from ALS diagnosis.
Neurobehavioral dysfunction was assessed with the Frontal Systems Behavior Scale (FrSBe), 10 a 46-item questionnaire. Each question is rated from 0 (almost never) to 5 (almost always). Fourteen questions are reverse-scored. The questionnaire includes a version for the patients (Self-Rating form) and a version for the caregivers (Family Rating form). Moreover, each item is rated indicating the behavior before the illness (premorbid period) and at the present time (postillness). Raw scores are converted to T scores according to gender, age, and years of education. These scores were used in data analyses. A T score between 60 and 64 is considered borderline while a T score Ն65 reflects frontal systems abnormalities. The FrSBe has 3 subscales: apathy, disinhibition, and executive dysfunction. The questionnaire, which has already been effectively used in ALS, [11] [12] [13] [14] has been translated in Italian and internally validated. 12 For the present study, we have considered the results of the premorbid and postillness Family Rating forms. If a patient had a score reflecting a frontal systems abnormality both in the in the premorbid form and the postillness form, he or she was considered pathologic only if there was an increase of at least 10 points at the T score between the premorbid and the postillness form. This difference was the median increase of the score observed in a previous series of patients with ALS followed in our center.
In order to exclude that FrSBe overall score or the score of one of its subscales was influenced by the declining of ALS disability, a progression rate of the disability scale (Amyotrophic Lateral Sclerosis Functional Rating Scale-revised [ALSFRS-R]) was calculated as follows: [48 Ϫ ALSFRS-R score at the time of the interview]/time in months where 48 is the maximum ALSFRS-R score. The progression rate was then correlated to FrSBe scores.
All patients were prospectively followed with clinic or home visits scheduled at 2 to 3 months interval. Enteral nutrition (EN) and noninvasive ventilation (NIV) were proposed according to the current clinical guidelines. 15 Both interventions are given free of charge by the Italian National Health System. We have considered as NIV-treated each patient who was prescribed the use of NIV and used it for at least 1 day (intention-to-treat analysis). A patient was defined tolerant to NIV if he or she was able to use the ventilator for at least 4 consecutive hours/day.
Statistical analysis.
Survival was calculated to death/tracheostomy or censoring date (June 30, 2011), using the Kaplan-Meier method, and compared with the log-rank test. Multivariable analysis was performed with Cox proportional hazards model (stepwise backward). EN and NIV were included as timedependent variables. Correlations were calculated with Pearson coefficient. No patient was lost to follow-up. A p level Ͻ0.05 was considered significant. All tests were 2-tailed. Statistical analyses were carried out using SPSS 18.0 (SPSS, Chicago, IL).
Standard protocol approvals, registrations, and patient consents.
The study design was approved by the institutional Ethical Committee of our center. Patients and caregivers signed a written informed consent. Database was managed according to the Italian law for the protection of privacy.
RESULTS
The 128 patients included 71 men and 57 women, with a mean age at onset of 64.7 years (SD 11; range 25.4 -87.4). The mean disease duration at time of interview was 1.1 year (SD 0.9). Ninety-two patients (71.9%) had a spinal onset and 36 (28.9%) a bulbar onset. According to FrSBe (Family rating form), 41 patients (32.0%) had an overall score Ն65, indicating neurobehavioral dysfunction; apathy was detected in 52 patients (40.6%), disinhibition in 23 (18.0%), and dysexecutive behavior in 44 (34.4%). Nine patients (7.0%) had an isolated dysexecutive behavior. The demographic and clinical differences between patients with and without neurobehavioral dysfunction are shown in the table. No correlation was found between total FrSBe score and its subscores and the ALSRFS-R progression rate, indicating that FrSBe findings were not related to the progression of the disease. EN and NIV were performed with similar frequencies in patients with and without neurobehavioral dysfunction (EN: neurobehavioral dysfunction 11 , A) . When considering only the patients without neurobehavioral dysfunction, those subjects with a pathologic score at the dysexecutive behavior subscale had significantly a shorter survival than those without a pathologic score undergoing NIV) and 2 a normal overall FrSBe score (6.5% of those undergoing NIV) ( p ϭ 0.03); however, both patients with a normal overall FrSBe score had an isolated dysexecutive behavior. Tolerance to NIV, as indicated by the ability to perform NIV for at least 4 consecutive hours/day, was lower in patients with neurobehavioral dysfunction (5 patients vs 1 patient with normal FrSBe score, who however had an isolated dysexecutive behavior). The negative effect of comorbid neurobehavioral dysfunction on survival persisted in a multivariate model that included neurobehavioral dysfunction, age, gender, site of onset (bulbar vs spinal), time delay to diagnosis, NIV, EN, ALSFRS-R score at diagnosis, and forced vital capacity percent of predicted (FVC%) at diagnosis (hazard ratio 1.72; 95% confidence interval 1.22-2.92; p ϭ 0.02). The presence of dysexecutive behavior in patients without comorbid neurobehavioral dysfunction remained significant in a multivariable model including dysexecutive behavior, age, gender, site of onset (bulbar vs spinal), time delay to diagnosis, NIV, EN, ALSRFRS-R score at diagnosis, and FVC% at diagnosis (hazard ratio 2.56; 95% confidence interval 1.20 -4.11; p ϭ 0.03).
DISCUSSION
In this study we have assessed the effect of neurobehavioral impairment, evaluated with FrSBe, in a population-based series of patients with ALS. We have found that the presence of neurobehavioral impairment was significantly correlated to shorter patient survival and that subjects with dysexecutive behavior but without neurobehavioral impairment have a worse outcome than patients cognitively spared or with impairment limited to other neurobehavioral domains. This negative effect was independent from other prognostic factors, as indicated by the multivariable model. In our series, the negative effect of neurobehavioral impairment on survival was partly due to the reduced benefit of NIV and EN.
The frequency of neurobehavioral dysfunction in our epidemiologic series is in the range of literature. 11, 12, 14, 16 The effect of cognitive impairment and FTD on survival of patients with ALS have been assessed in a few studies in the last decade. A shorter survival of patients with ALS-FTD was first reported in a series of 81 patients attending a tertiary ALS center. 5 In that study, patients with ALS-FTD were those subjects who met Neary's criteria for FTD or had abnormal executive function on neuropsychological testing. A recent population-based prospective study on Irish patients with ALS showed that comorbidity with FTD significantly reduced survival and, similarly to our series, patients without FTD but with dysexecutive dysfunction had a shorter survival. 6 Another study, comparing patients with a simultaneous onset of ALS and FTD symptoms to those with an onset with FTD symptoms and a later development of motor symptoms, demonstrated that the co-occurrence of ALS and FTD carried a significantly shorter survival. 17 Conversely, 3 studies performed on clinical series did not find any effect of cognitive impairment on ALS outcome after controlling for ALS severity. 16, 18, 19 The observed discrepancies between these reports could be due to several reasons. First, some studies were underpowered to detect differences of survival due to the few patients included 16, 18, 19 ; second, the different setting of the various studies, ranging from tertiary ALS centers to population-based series, probably determined a patient selection bias in some of them 20 ; third, the different neuropsychological batteries used could have caused a different rate of detection of neurobehavioral impairment.
Our study has some strengths. The major strengths are the representativeness of the ALS population, with a complete ascertainment of cases from a population-based epidemiologic register 7 and the enrollment of 128 out of the 132 incident cases, and the longitudinal prospective design.
The major limitation of our study is that for the assessment of cognitive impairment we did not perform a full series of cognitive testing but we relied on the FrSBe questionnaire. In fact, FrSBe is heavily based on the subjective feeling of the caregiver, which can be confounded by the loss of patients' physical abilities, as well as by his or her mood status. However, the FrSBe is a simple and validated test allowing the detection of behavioral dysfunction in patients with ALS, comparing the premorbid to the present time behavior according to the caregivers' rating. [11] [12] [13] [14] Using this questionnaire we could demonstrate that behavioral dysfunction has a great negative influence on patient survival.
We found that neurobehavioral dysfunction, and isolated dysexecutive behavior as well, significantly reduced patient survival related to the use of NIV and EN. Interestingly, patients with neurobehavioral dysfunction underwent NIV and EN with a similar frequency as patients without behavioral dysfunction. The reasons why neurobehavioral dysfunction impairs the use of these interventions are unclear. It is has been reported that compliance with both interventions, in particular NIV, is reduced in cognitively impaired patients with ALS, but this assumption was based only on indirect data, such as the time delay after the neurologist recommendation or the modality of use of EN and NIV. 5 In our series, the 30-day mortality rate after NIV initiation, a marker of re-duced compliance, was significantly higher in patients with neurobehavioral dysfunction and in those with isolated dysexecutive behavior than in patients with no neurobehavioral dysfunction. Moreover, more patients with neurobehavioral dysfunction and isolated dysexecutive behavior had a reduced tolerance to NIV. This finding deserves further study, with an ad hoc prospective assessment of the use of NIV and EN in patients with ALS with and without cognitive impairment. However, poor compliance with NIV and EN does not fully explain the negative effect of neurobehavioral dysfunction on ALS survival, which is likely to be related to other biological or clinical factors.
The role of comorbid cognitive and neurobehavioral dysfunction in the clinical course of ALS is becoming increasingly evident, including the reduced efficacy of life-prolonging therapies. Therefore, measures of patients' cognitive and behavioral assessment should be included both in the diagnostic workup of patients with ALS and in the evaluation of patients for enrollment in clinical trials. 
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